Table 3 Characteristics of patients with and without acute biliary events

Age (years)^a*

66.2 ± 13.5

56.6 ± 19.7

Male^b

132 (67.7)

109,399 (68.6)

 1996–2000

60 (30.8)

48,844 (30.6)

 2001–2005

73 (37.4)

59,424 (37.3)

 2006–2010

62 (31.8)

51,103 (32.1)

 Diabetes mellitus^b*

63 (37.4)

38,075 (23.9)

 Chronic obstructive pulmonary disease^b

10 (5.1)

7918 (5.0)

 Malignancy^b

12 (6.2)

6712 (4.2)

 End-stage renal disease^c

2 (1.0)

1998 (1.3)

 Connective tissue disease^c

0 (0.0)

1151 (0.7)

 Acquired immunodeficiency syndrome^c

1 (0.5)

562 (0.4)

 Liver cirrhosis^c

1 (0.5)

323 (0.2)

 Transplantation^c*

1 (0.5)

137 (0.1)

 Pneumoconiosis^c

0 (0)

85 (0.1)

Low income^b

5 (2.6)

4830 (3.0)

Total duration of anti-TB treatment

266.9 ± 99.7

260.4 ± 105.8

  No. of days covered by isoniazid^a

47.7 ± 18.6

50.0 ± 11.2

  No. of days covered by rifamycin^a*

48.9 ± 13.4

51.7 ± 11.2

  No. of days covered by ethambutol^a

51.2 ± 11.4

50.8 ± 13.1

  No. of days covered by pyrazinamide^a

39.9 ± 21.3

42.5 ± 20.4

  No. of days covered by isoniazid^a*

134.4 ± 52.2

142.4 ± 53.4

  No. of days covered by rifamycin^a*

140.1 ± 37.9

152.5 ± 32.8

  No. of days covered by ethambutol^a

145.2 ± 35.6

141.9 ± 42.2

  No. of days covered by pyrazinamide^a

67.8 ± 44.9

69.3 ± 45.8